35.26
10-January-25 15:45:00
15 minutes delayed
Stocks
-2.36
-6.27%
Today's range
33.70 - 38.98
ISIN
N/A
Source
NASDAQ
Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio
18 Jan 2024 07:00:00 By Nasdaq GlobeNewswire
Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04 Jan 2024 07:00:00 By Nasdaq GlobeNewswire
Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
07 Dec 2023 07:00:00 By Nasdaq GlobeNewswire